European Journal of Clinical Pharmacology

, Volume 27, Issue 2, pp 227–232 | Cite as

Effect of cimetidine on the metabolism of cholephilic dyes in Gilbert's syndrome

  • K. Kutz
  • M. Deres
Originals

Summary

The metabolism of indocyanine green, bromsulphophthalein and bilirubin was studied before and after a treatment for 2 weeks with cimetidine 1.0 g/day in 12 subjects with Gilbert's syndrome. There was no effect on the plasma clearance of indocyanine green and bromsulphophthalein, on the maximal biliary excretion capacity of bromsulphophthalein, on serum bilirubin concentrations or on the biliary metabolites of bromsulphophthalein and bilirubin. It is concluded that in Gilbert's syndrome two weeks of treatment with cimetidine had no effect on liver blood flow or on conjugation mechanisms which were independent of cytochrome P450.

Key words

cimetidine indocyanine green bromsulphophthalein bilirubin Gilbert's syndrome drug metabolism drug conjugation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jones RH, Rudge CJ, Bewick M, Parsons V, Weston MJ (1978) Cimetidine: prophylaxis against upper gastrointestinal hemorrhage after renal transplantation. Br Med J 1: 398–400Google Scholar
  2. 2.
    Brimblecombe RW, Duncan WAM, Durant GJ, Emmett JC, Ganellin CR, Parsons ME (1975) Cimetidine — a nonthiourea H2-receptor antagonist. J Int Med Res 3: 86–92Google Scholar
  3. 3.
    Serlin MJ, Challiner M, Park BK, Turcan PA, Breckenridge AN (1980) Cimetidine potentiates the anticoagulant effect of warfarin by inhibition of drug metabolism. Biochem Pharmacol 29: 1971–1972Google Scholar
  4. 4.
    Desmond PV, Patwardhan R, Parker R, Schenker S, Speeg KV Jr (1980) Effect of cimetidine and other antihistaminics on the elimination of aminopyrin, phenacetin and caffein. Life Sci 26: 1261–1268Google Scholar
  5. 5.
    Klotz U, Antilla VJ, Reimann J (1979) Cimetidine/diazepam interaction (letter). Lancet 2: 699Google Scholar
  6. 6.
    Bircher J, Küpfer A, Gikalov I, Preisig R (1976) Aminopyrine demethylation measured by breath analysis in health and in cirrhosis of the liver. Clin Pharmacol Ther 20: 484–492Google Scholar
  7. 7.
    Schillings RT, Schrader SR, Ruelins HW (1971) Urinary metabolites of lorazepam in humans and four animals species. Arzneimittelforsch 21: 1059–1065Google Scholar
  8. 8.
    Johnson RF, Schenker S, Roberts RK (1979) Plasma binding of benzodiazepines in humans. J Pharm Sci 68: 1320–1322Google Scholar
  9. 9.
    Patwardhan RV, Yarborough GW, Desmond PV, Johnson RF, Schenker S, Speeg KV Jr (1980) Cimetidine spares the glucuronidation of lorazepam and oxazepam. Gastroenterology 79: 912–916Google Scholar
  10. 10.
    Feely J, Wilkinson GR, Wood AJJ (1981) Reduction of liver blood flow and propranolol metabolism by cimetidine. N Engl J Med 304: 692–695Google Scholar
  11. 11.
    Garg DC, Weidler DJ, Jallad NS, Eshelman FN (1982) The effect of ranitidine and cimetidine on hepatic blood flow (abstract). Clin Pharmacol Ther 31: 228Google Scholar
  12. 12.
    Lebrec D, Goldfarb G, Benhamou JP (1981) Reduction in liver blood flow by cimetidine (letter). N Engl J Med 305: 100Google Scholar
  13. 13.
    Berk PD, Bloomer JR, Howe RB, Berlin NI (1970) Constitutional hepatic dysfunction (Gilbert's syndrome). A new definition based on kinetic studies with unconjugated radio bilirubin. Amer J Med 49: 296–305Google Scholar
  14. 14.
    Black M, Billing BH (1969) Hepatic bilirubin UDP-glucuronyl transferase activity in liver disease and Gilbert's syndrome. N Engl J Med 280: 1266–1271Google Scholar
  15. 15.
    Berk PD, Blaschke TF, Waggoner JG (1972) Defective bromsulphthalein clearance in patients with constitutional hepatic dysfunction (Gilbert's syndrome). Gastroenterology 63: 472–481Google Scholar
  16. 16.
    Martin JF, Vierling JM, Wolkoff AW, Scharschmidt BF, Vergalla J, Wagoner JG, Berg PD (1976) Abnormal hepatic transport of indocyanine green in Gilbert's syndrome. Gastroenterology 70: 385–391Google Scholar
  17. 17.
    Ohkubo H, Okuda K, Jida S (1981) A constitutional unconjugated hyperbilirubinaemia combined with indocyanine green intolerance: a new functional disorder? Hepatology 1: 319–324Google Scholar
  18. 18.
    Fevery J, Verwilghen R, Than TG, De Groote J (1979) Glucuronidation of bilirubin and the occurence of pigment gall stones in patients with chronic haemolytic diseases. Eur J Clin Invest 10: 219–226Google Scholar
  19. 19.
    Preisig R, Williams R, Sweeting J, Bradley SE (1966) Changes in sulphobromphtalein transport and storage by the liver during viral hepatitis in man. Amer J Med 40: 170–183Google Scholar
  20. 20.
    Caesar J, Shaldon S, Chiandussi L, Guevara L, Sherlock S (1961) The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function. Clin Sci Mol Med 21: 43–57Google Scholar
  21. 21.
    Michaelsson M, Nosslin B, Sjölin S (1965) Plasma bilirubin determination in the newborn infant. A methodological study with special reference to the influence of hemolysis. Pediatrics 35: 925–931Google Scholar
  22. 22.
    Van Roy FP, Heirwegh KPM (1968) Determination of bilirubin glucuronyl transferase with bilirubin as acceptor. Biochem J 107: 507–518Google Scholar
  23. 23.
    Kutz K, Kandler H, Gugler R, Fevery J (1984) Effect of clofibrate on the metabolism of bilirubin, bromsulphthalein and indocyanine green and on biliary lipid composition in Gilbert's syndrome. Clin Sci 66: 389–397Google Scholar
  24. 24.
    Paumgartner G, Horak W, Probst P, Grabner G (1971) Effect of phenobarbital on bile flow and bile salt excretion in the rat. Nauny-Schmiedebergs Arch Pharmacol 270: 98–101Google Scholar
  25. 25.
    Abell LL, Levy BB, Brodie BB, Kendall FE (1952) A simplified method for the estimation of total cholesterol in serum and demonstration of its specifity. J Biol Chem 195: 357–366Google Scholar
  26. 26.
    Bartlett GR (1950) Phosphorus assay in column chromatographie. J Biol Chem 234: 466–468Google Scholar
  27. 27.
    Thomas WJ, Hofmann AF (1973) A simple calculation of the lithogenic index of bile: expressing biliary lipid composition on rectangular coordinates. Gastroenterology 65: 698–700Google Scholar
  28. 28.
    Quarfordt SH, Hildermann HL, Valle T, Ladell E (1971) Compart mental analysis of BSP-transport in normal patients and patients with hepatic dysfunction. Gastroenterology 60: 246–255Google Scholar
  29. 29.
    Häcki W, Bircher J, Preisig R (1976) A new look at the plasma disappearance of sulphobromophthalein (BSP): correlation with the BSP-transport maximum and the hepatic plasma flow in man. J Lab Clin Med 88: 1019–1031Google Scholar
  30. 30.
    Lienert GA (1973) Verteilungsfreie Methode in der Biostatistik, 2nd edn. H. Hain, Meisenheim am Glar, FRGGoogle Scholar
  31. 31.
    Scharschmidt B, Gollan JL (1979) Current concepts of bilirubin metabolism and hereditary hyperbilirubinemia. Edited by Popper H, Schaffner F (ed) Progress in liver diseases, vol 6. Grune and Stratton, New York, pp 187–211Google Scholar
  32. 32.
    Leevy CM, Bender J, Silverberg M, Neylor J (1963) Physiology of dye extraction by the liver: comparative studies of sulphobromphthalein and indocyanine green. An NY Acd Sci 111: 161–175Google Scholar
  33. 33.
    Fevery J, Blankaert N, Heirwegh KPM, Preaux AM, Berthelot P (1977) Unconjugated bilirubin and an increased proportion of bilirubin monoconjugates in the bile of patients with Gilbert's syndrome and Crigler-Najjar disease. J Clin Invest 60: 970–979Google Scholar
  34. 34.
    Daneshmend TK, Ene MD, Parker G, Roberts CJC (1984) Effects of chronical oral cometidine on apparent liver blood flow and hepatic microsomal enzyme activity in man. Gut 25: 125–128Google Scholar
  35. 35.
    Reyes H, Levy AJ, Gatmaitan C, Arias M (1971) Studies of Y and Z, two hepatic cytoplasmatic organic anion-binding proteins: effect of drugs, chemicals, hormones and cholestases. J Clin Invest 50: 2242–2252Google Scholar

Copyright information

© Springer-Verlag 1984

Authors and Affiliations

  • K. Kutz
    • 1
    • 2
  • M. Deres
    • 1
  1. 1.Medizinische PoliklinikUniversity of BonnBonnFederal Republik of Germany
  2. 2.Department of Experimental TherapeuticsSandoz Ltd.BasleSwitzerland

Personalised recommendations